AI therapeutics firm Deep Genomics inks Series B

Toronto-based Deep Genomics, an artificial intelligence therapeutics company, has raised US$40 million in Series B funding.

7 January 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles